Alliant acquires two new drugs

6 June 2004

Alliant Pharmaceuticals, an emerging US pediatric specialty pharmaceutical company, says that it has bought the exclusive US marketing rights to two, unspecified, products for attention-deficit hyperactivity disorder from Mallinckrodt, a business unit of Tyco Healthcare. Terms of the acquisition agreement were not disclosed.

Mark Pugh, chief executive of Alliant, said that "the acquisition of these two therapies is a significant milestone for our long-term growth which will form the basis for our aggressive development and marketing of products focused in the area of pediatrics and pediatric specialties."

In 2003, the company noted, the total ADHD market in the USA was worth approximately $1.8 billion and it grew at an average annual growth rate of 20% from 2002 to 2003. The market is expected to reach $4 billion in the next five years. "Our strategy is to acquire products that will provide solutions to unmet medical needs, in growing markets, and deliver value to the patient and the physician," said Mr Pugh.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight